newsfilter
← Latest News
PR Newswire·

Curis to Report Fourth Quarter 2025 Financial and Operating Results and Host Conference Call and Webcast on March 19, 2026

Curis, Inc. (NASDAQ: CRIS), a biotechnology company focused on the development of emavusertib (CA-4948), an orally available, small molecule IRAK4...